Clinical Trials Logo

Clinical Trial Summary

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the clinical response of sunitinib malate in patients with Kaposi sarcoma (KS) in Uganda and Kenya.

II. Compare clinical response rates in endemic versus epidemic (AIDS) KS. III. Determine the safety and tolerability of sunitinib malate in patients with endemic or epidemic (AIDS) KS.

SECONDARY OBJECTIVES:

I Monitor the impact of sunitinib malate on underlying HIV-1 and Kaposi sarcoma-associated herpesvirus (KSHV) viral infection (HIV-1 plasma RNA and KSHV cell-associated DNA).

II. Evaluate morphological changes in KS lesions after treatment. III. Determine the pharmacokinetic profile of sunitinib malate in patients with KS.

IV Evaluate KSHV gene expression in endemic and epidemic KS lesions in patients in Uganda and Kenya.

OUTLINE: This is a multicenter study. Patients are stratified according to HIV-serostatus (endemic [HIV-seronegative] vs epidemic [HIV-seropositive/AIDS] kaposi sarcoma).

Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

Patients undergo tumor tissue and blood sample collection periodically for correlative and pharmacokinetic studies. Samples are analyzed for CD4 lymphocyte counts, HIV-1 plasma RNA levels, KSHV specific antibodies, expression pattern of KSHV in vitro and in vivo, expression of latently versus lytically expressed genes in tumor tissue, and plasma concentrations of sunitinib malate and its active metabolite, SU12662.

After completion of study treatment, patients are followed every 6 weeks. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00521092
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Withdrawn
Phase Phase 2
Start date January 2009

See also
  Status Clinical Trial Phase
Completed NCT03596918 - Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
Not yet recruiting NCT05567601 - Doxil/Caelyx BE Study Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Completed NCT00064142 - Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Phase 2
Terminated NCT00020683 - A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma Phase 2
Completed NCT00003350 - Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Phase 3
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Active, not recruiting NCT05510973 - Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi N/A
Recruiting NCT05510908 - Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
Withdrawn NCT02137564 - Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma Phase 2
Completed NCT01016730 - Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Phase 1
Completed NCT01057121 - Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Phase 1/Phase 2